Tumor spectrum, tumor latency and tumor incidence of the Pten-deficient mice

PLoS ONE

Volumn 2, Issue 11, 2007, Pages

  Lu, Tsai Ling ^a   Chang, Junn Liang ^b   Liang, Chih Chia ^a   You, Li Ru ^a   Chen, Chun Ming ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CRE RECOMBINASE; PROTEIN TYROSINE PHOSPHATASE; TUMOR SUPPRESSOR PROTEIN; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4 HYDROXYTAMOXIFEN; 4-HYDROXYTAMOXIFEN; CHROMONE DERIVATIVE; DRUG DERIVATIVE; INTEGRASE; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, MOUSE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL LINEAGE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MODEL; DRUG RESEARCH; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME INHIBITION; EPIDERMIS; EXON; FEMALE; GENE DELETION; GENE MUTATION; INTESTINE CANCER; INTESTINE EPITHELIUM; LATENT PERIOD; LOXP SITE; LYMPHOID CELL; LYMPHOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; PROTEIN DEFICIENCY; PROTEIN DEPLETION; PROTEIN FUNCTION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TISSUE SPECIFICITY; TISSUE TYPES; TUMOR GROWTH; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; GENETIC RECOMBINATION; GENETICS; INCIDENCE; MOUSE STRAIN; PATHOLOGY; PHYSIOLOGY;

MUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CHROMONES; DISEASE-FREE SURVIVAL; FEMALE; INCIDENCE; INTEGRASES; MALE; MICE; MICE, INBRED STRAINS; MORPHOLINES; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PTEN PHOSPHOHYDROLASE; RECOMBINATION, GENETIC; TAMOXIFEN;

EID: 43349100564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001237     Document Type: Article

References (44)

1. Stambolic, V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29-39.
2. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL (1998) The PTEN/MMAC1 tumor suppressor phosphatase function as a negative regulator of the phosphoinosidde 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95: 15587-15591.
3. Maehama T, Dixon JE (1999) PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9: 125-128.
4. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the P13K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6: 184-192.
5. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
6. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
7. Teng DH, Hu R, Lin H, Davis T, Iliev D, et al. (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57: 5221-5225.
8. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348-355.
9. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, et al. (2000) High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 60: 3605-3611.
10. Sun H, Lesche R, Li DM, Liliental J, Zhang H, et al, (1999) PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc Natl Acad Sci U S A 96: 6199-6204.
11. Suzuki A, de laPompa JL, Slambolic V, Elia AJ, Sasaki T, et al. (1998) High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8: 1169-1178.
12. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, et al. (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 96: 1563-1568.
13. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, et al. (2002) Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad-Sci U S A 99: 2884-2889.
14. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, et al. (2005) Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
15. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, et al. (2003) PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3: 117-130.
16. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, et al. (2003) Nkx3. 1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63: 3886-3890.
17. Di Cristofano A, De Acetis M, Koff A, Gordon-Cardo C, Pandolfi PP (2001) Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27: 222-224.
18. Kwan KM (2002) Conditional alleles in mice: practical considerations for tissue-specific knockouts. Genesis 32: 49-62.
19. Metzger D, Chambon P (2001) Site- and time-specific gene targeting in the mouse. Methods 24: 71-80.
20. Wang S, Gao J, Lei Q, Rozengurt N, Pritchard C, et al. (2003) Prostate-specific deletion of the routine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4. 209-221.
21. Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, et al. (2005) Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. Cancer Res 65: 5730-5739.
22. Backman SA, Ghazarian D, So K, Sanchez O, Wagner KU, et al. (2004) Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc Nad Acad Sci U S A 101: 1725-1730
23. Trourian LC, Niki M, Dotan ZA, Koutcher JA, Di Cristofano A, et al. (2003) Pten dose dictates cancer progression in the prostate. PLoS Biol 1: F59.
24. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, et al. (2006) Pica dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells, Nature 441: 475-482.
25. Wang S, Garcia AJ, Wu M, Lawson DA, Witte ON, et al. (2006) Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A 103: 1480-1485.
26. He XC, Yiun T, Grindley JC, Tian Q, Sato T, et al. (2007) PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 39: 189-198.
27. Badea TC, Wang Y, Nathans J (2003) A noninvasive genetic/pharmacologic strategy for visualizing cell morphology and clonal relationships in the mouse. J Neurosci 23: 2314-2322.
28. Lesche R, Groszer M, Gao J, Wang Y, Messing A, et al. (2002) Cre/ loxP-mediated inactivation of the murine Pten tumor suppressor gene. Genesis 32: 148-149.
29. Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp, A, et al. (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294: 2186-2189.
30. Sakai A, Thieblemont C, Wellmann A, Jaffe ES, Raffela M (1998) PTEN gene alterations in lymphoid neoplasms. Blood 92: 3410-3415.
31. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, et al. (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57: 4997-5000.
32. Risinger JI, Hayes AK, Berchuck A, Barrett JC (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57: 4736-4738.
33. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, et al. (1998) Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1: 507-515.
34. Sansal I, Sellers WR (2004) The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963.
35. Eng C (2000) Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37: 828-830.
36. Freeman D, Lesche R, Kertesz N, Wang S, Li G, et al. (2006) Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 66: 6492-6496
37. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB (2000) In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 6: 880-886.
38. Bandar VM, Sweeney-Gotsch B, Andreeff M, Mills GB, McConkey DJ (2002) Inhibition of the phosphatidylinositol 3 -kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo. Mol Cancer Ther 1: 989-997.
39. Shukla S, Maclennan GT, Hartman DJ, Fu P, Resitick MI, et al. (2007) Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. Int J Cancer 121: 149-1432.
40. Kwon CH, Zhu X, Zhang J, Baker SJ (2003) mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci U S A 100: 12923-12928.
41. Milam MR, Celestino J, Wu W, Broaddus RR, Schmeler KM, et al. (2007) Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am J Obstet Gynecol 196: 247 e241-245.
42. Mao X, Fujiwara Y, Orkin SH (1999) Improved reporter strain for monitoring Cre recombinase-mediated DNA excisions in mice. Proc Natl Acad Sci U S A 96: 5037-5042.
43. Chen CM, Behringer RR (2004) Ovcal regulates cell proliferation, embryonic development, and tumorigenesis. Genes Dev 18: 320-332.
44. Chen CM, Chang JL, Behringer RR (2004) Tumor formation in p53 mutant ovaries transplanted into wild-type female hosts. Oncogene 23: 7722-7725.